Novel Mitochondrial Base Editor
Therapeutics for Mitochondrial Genetic Disorders
Novel Mitochondrial Base Editor
Therapeutics for Mitochondrial Genetic Disorders
주식회사 엣진
To build a better future
through disruptive innovations in healthcare
Even more than 1 in every 5,000 individuals suffer from a mitochondrial diseases,
currently there is no highly effective treatment or cure for patients with a disease.
Edgene is developing first-in-class gene therapeutics
to correct pathogenic mitochondrial gene mutations
using own/proprietary state-of-the-art gene editing technologies for patients.
currently there is no highly effective treatment or cure for patients with a disease.
Edgene is developing first-in-class gene therapeutics
to correct pathogenic mitochondrial gene mutations
using own/proprietary state-of-the-art gene editing technologies for patients.
Copyright @ EDGENE. All Right Reserved
Privacy policy